Want to join the conversation?
$CSRA said beginning in FY17, it intends to provide guidance for annual periods rather than quarters, since the timing of the spin-off transaction was not conducive to that approach in FY16. $CSRA expects 4Q16 revenue in the range of $1.28-1.33Bil. Adjusted EBITDA is expected to be $214-226MM and adjusted diluted EPS to be $0.45-0.49 in 4Q16.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?